All In Biotech

Drug Trial Radar · NCT06605599

Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Bipolar I or II Disorder

Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Fixed-dose Study to Evaluate the Efficacy, Safety, and Tolerability of ABBV-932 in Subjects With Depressive Episodes Associated With Bipolar I or II Disorder

Last checked: Nov 19, 2026Latest source record: Oct 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 161 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

161

Actual

Start

Oct 15, 2024

Primary completion

Nov 12, 2025

Study completion Dec 10, 2025

Sponsor

Lead sponsor
AbbVieAbbVie (ABBV)
Sponsor type
Industry
First posted
Sep 20, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Bipolar disorder is a severe chronic mood disorder that affects up to 4% of the adult population in the United States. This study will assess how safe and effective ABBV-932 is in treating participants with bipolar I or II disorder. ABBV-932 is an investigational drug being developed for the treatment of depressive episodes in adult participants with bipolar I or II disorder. Study doctors put participants in 1 of 4 groups, called treatment arms. There is a 1 in 4 chance that a participant will be assigned to placebo. Around 160 adult participants with bipolar I or II disorder will be enrolled in approximately 40 sites worldwide. Participants will receive oral capsules of ABBV-932 or matching placebo once daily for 6 weeks. The treatment period will be followed by a safety follow-up (SFU) period for 4 weeks. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular weekly visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

Conditions

  • Bipolar I Disorder
  • Bipolar II Disorder

Interventions

  • ABBV-932Drug

    Oral Capsule

  • Placebo for ABBV-932Drug

    Oral Capsule

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total ScoreTime frame: Up to Week 6

Locations

40 sites in 3 countries. Site status is shown where the registry gives one.

  • Harmonex /ID# 267504

    Dothan, Alabama

  • Advanced Research Center /ID# 267716

    Anaheim, California

  • Axiom Research /ID# 267518

    Colton, California

  • Collaborative Neuroscience Research - Garden Grove /ID# 267654

    Garden Grove, California

  • Sun Valley Research Center /ID# 267708

    Imperial, California

  • Alliance for Research Alliance for Wellness /ID# 267492

    Long Beach, California

  • Excell Research /ID# 267541

    Oceanside, California

  • Viking Clinical Research Center - Temecula /ID# 267634

    Temecula, California

  • Accel Research Sites Network - St. Pete /ID# 267463

    Largo, Florida

  • GMI Florida - Central Miami Medical Institute /ID# 267566

    Miami, Florida

  • Allied Biomedical Res Inst Inc /ID# 267481

    Miami, Florida

  • K2 Medical Research - Orlando - South Orlando Avenue /ID# 267567

    Orlando, Florida

  • Segal Trials - West Broward Outpatient Research Site /ID# 267947

    Tamarac, Florida

  • Benchmark Research /ID# 267626

    Shreveport, Louisiana

  • CenExel /ID# 267675

    Gaithersburg, Maryland

  • Arch Clinical Trials /ID# 267507

    St Louis, Missouri

  • Duplicate_Oasis Clinical Research, LLC /ID# 267969

    Las Vegas, Nevada

  • Center For Emotional Fitness - Cherry Hill /ID# 267661

    Cherry Hill, New Jersey

  • Bio Behavioral Health /ID# 267493

    Toms River, New Jersey

  • Neurobehavioral Research /ID# 267564

    Cedarhurst, New York

  • New Hope Clinical Research - Inpatient unit /ID# 267465

    Charlotte, North Carolina

  • Quest Therapeutics of Avon Lake /ID# 267558

    Avon Lake, Ohio

  • OSU Psychiatry Department /ID# 267730

    Columbus, Ohio

  • Sooner Clinical Research /ID# 267639

    Oklahoma City, Oklahoma

  • Lehigh Center for Clinical Research /ID# 267451

    Allentown, Pennsylvania

  • Suburban Research Associates - Media /ID# 267621

    Media, Pennsylvania

  • Coastal Carolina Research Center, LLC /ID# 267550

    Charleston, South Carolina

  • FutureSearch Trials of Dallas /ID# 267715

    Dallas, Texas

  • Perceptive Pharma Research /ID# 267563

    Richmond, Texas

  • Grayline Research Center /ID# 267466

    Wichita Falls, Texas

  • Northwest Clinical Research Center /ID# 267505

    Bellevue, Washington

  • Core Clinical Research /ID# 268534

    Everett, Washington

  • Kaku Mental Clinic /ID# 268020

    Fukuoka, Fukuoka, Japan

  • Kuramitsu Hospital /ID# 268751

    Fukuoka, Fukuoka, Japan

  • Kokura Mental Clinic /ID# 268031

    Kitakyushu, Fukuoka, Japan

  • Kawamura Mental Clinic /ID# 268325

    Sapporo, Hokkaido, Japan

  • Yutaka Clinic /ID# 268026

    Sagamihara, Kanagawa, Japan

  • INSPIRA Clinical Research /ID# 267041

    San Juan, Puerto Rico, Puerto Rico

  • Instituto De Neurologia Dra. Ivonne Fraga, Psc /ID# 267065

    San Juan, Puerto Rico, Puerto Rico

  • BDH Research /ID# 267025

    San Juan, Puerto Rico, Puerto Rico

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.